Identification of anaplastic lymphoma kinase as a potential therapeutic target in Basal Cell Carcinoma

Oncotarget

Volumn 4, Issue 12, 2013, Pages 2237-2248

  Ning, Hanna ^a   Mitsui, Hiroshi ^a   Wang, Claire Q F ^a   Suárez Fariñas, Mayte ^a   Gonzalez, Juana ^a   Shah, Kejal R ^b   Chen, Jie ^c   Coats, Israel ^a   Felsen, Diane ^c   Carucci, John A ^d   Krueger, James G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Basal cell carcinoma; Cancer; Oncogenic kinases; Therapy

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; COMPLEMENTARY DNA; CRIZOTINIB; MESSENGER RNA; MIDKINE; PLEIOTROPHIN; PROTEIN CCND2; PROTEIN TYROSINE KINASE; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; UNCLASSIFIED DRUG;

ARTICLE; BASAL CELL CARCINOMA; CELL PROLIFERATION; CONTROLLED STUDY; DNA MICROARRAY; DRUG TARGETING; ENZYME ANALYSIS; ENZYME PHOSPHORYLATION; EPIDERMIS; GENE EXPRESSION PROFILING; GENE TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; LASER CAPTURE MICRODISSECTION; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE ALK; PROTEIN EXPRESSION;

ANIMALS; CARCINOMA, BASAL CELL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; HUMANS; KERATINOCYTES; LASER CAPTURE MICRODISSECTION; MICE; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 84891942299     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1357     Document Type: Article

References (39)

1. Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, and Coldiron BM. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010: 146; 283-287
2. Walling HW, Fosko SW, Geraminejad PA, Whitaker DC, and Arpey CJ. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev. 2004: 23; 389-402
3. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008: 8; 167-170
4. Ingham PW, Nakano Y, and Seger C. Mechanisms and functions of Hedgehog signaling across the metazoa. Nat Rev Genet. 2011: 12; 393-406
5. Kar S, Deb M, Sengupta D, Shilpi A, Bhutia SK, and Patra SK. Intricacies of hedgehog signaling pathways: a perspective in tumorigenesis. Exp Cell Res. 2012: 318; 1959-1972
6. Gailani MR and Bale AE. Developmental genes and cancer: role of patched in basal cell carcinoma of the skin. J Natl Cancer Inst. 1997: 89; 1103-1109
7. Rubin AI, Chen EH, and Ratner D. Basal-cell carcinoma. N Engl J Med. 2005: 353; 2262-2269
8. Iwasaki JK, Srivastava D, Moy RL, Lin HJ, and Kouba DJ. The molecular genetics underlying basal cell carcinoma pathogenesis and links to targeted therapeutics. J Am Acad Dermatol. 2012: 66; e167-178
9. Karve SJ, Feldman SR, Yentzer BA, Pearce DJ, and Balkrishnan R. Imiquinid: a review of basal cell carcinoma treatments. J Drugs Dermatol. 2008: 7; 1044-1051
10. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MB, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC, Jr., de Sauvage FJ, and Low JA. Inhibition of the hedgehog pathway in advanced basal cell carcinoma. N Engl J Med. 2009: 361; 1164-1172
11. LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, and Von Hoff DD. Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2011: 17; 2502-2511
12. Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T, Mori S, Ratzkin B, and Yamamoto T. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene. 1997: 14; 439-449
13. Stoica GE, Kuo A, Powers C, Bowden ET, Sale EB, Riegel AT, and Wellstein A. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem. 2002: 277; 35990-35998
14. Stoica GE, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C, Caughey DJ, Wen D, Karavanov A, Riegel AT, and Wellstein A. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem. 2001: 276; 16772-16779
15. Shiota M, Nakamura S, Ichinohasama R, Abe M, Akagi T, Takeshita M, Mori N, Fujimoto J, Miyauchi J, Mikata A, Nanba K, Takami T, Yamabe H, Takano Y, Izumo T, Nagatani T, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: A distinct clinicopathologic entity. Blood. 1995: 86; 1954-1960
16. Amin HM and Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood. 2007: 110; 2259-2267
17. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, et al. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature. 2007: 448 (7153): 561-566
18. Tothova Z and Wagner AJ. Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors. Curr Opin Oncol: 24; 409-413
19. Jazii FR, Najafi Z, Malekzadeh R, Conrads TP, Ziaee AA, Abnet C, Yazdznbod M, Karkhane AA, and Salekdeh GH. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J Gastroenterol. 2006: 12; 7104-7112
20. Ren H, Tan ZP, Zhu X, Crosby K, Haack H, Ren JM, Beausoleil S, Moritz A, Innocenti G, Rush J, Zhang Y, Zhou XM, Gu TL, Yang YF, and Comb MJ. Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer. Cancer Res. 2012: 72; 3312-3323
21. Azarova AM, Gautam G, and George RE. Emerging importance of ALK in neuroblastoma. Semin Cancer Biol. 2011: 21; 267-275
22. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, et al. Anaplastic Lymphoma Kinase Inhibition in Non-small-cell lung cancer. N Engl J Med. 2010: 363; 1693-1703
23. Camidge DR and Doebele RC. Targeting ALK-positive lung cancer - early successes and future challenges. Nat Rev Clin Oncol. 2012: 9; 268-277
24. O'Driscoll L, McMorrow J, Doolan P, McKiernan E, Mehta JP, Ryan E, Gammell P, Joyce H, O'Donovan N, Walsh N, and Clynes M. Investigation of the Molecular Profile of Basal Cell Carcinoma Using Whole Genome Microarrays. Mol Cancer. 2006: 5; 74
25. Tanese K, Fukuma M, Yamada T, Mori T, Yoshikawa T, Watanabe W, Ishiko A, Amagai M, Nishikawa T, and Sakamoto M. G-Protein-Coupled Receptor GPR49 is Up-Regulated in Basal Cell Carcinoma and Promotes Cell Proliferation and Tumor Formation. Am J Pathol. 2008: 173; 835-843
26. Yu M, Zloty D, Cowan B, Shapiro J, Haegert A, Bell RH, Warshawski L, Carr N, and McElwee KJ. Superficial, Nodular, and Morpheiform Basal-Cell Carcinomas Exhibit Distinct Gene Expression Profiles. J Invest Dermatol. 2008: 128; 1797-1805
27. Giuriato S, Foisseau M, Dejean E, Felsher DW, Al Saati T, Demur C, Ragab A, Kruczynski A, Schiff C, Delsol G, Meggetto F. Conditional TPM3-ALK and NPM-ALK Transgenic Mice Develop Reversible ALK-Positive Early B-Cell Lymphoma/Leukemia. Blood. 2010: 115; 4061-4070
28. Singh RR, Cho-Vega JH, Davuluri Y, Ma S, Kasbidi F, Milito C, Lennon PA, Drakos E, Medeiros LJ, Luthra R, Vega F. Sonic Hedgehog Signaling Pathway Is Activated in ALK-Positive Anaplastic Large Cell Lymphoma. Cancer Res. 2009: 69; 2550-2558
29. Weinstein IB and Joe AK. Mechanisms of Disease: oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol. 2006: 3; 448-457
30. Medves S and Demoulin J-B. Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies. J Cell Mol Med. 2012: 16; 237-248
31. Vanneman M and Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012: 12; 237-251
32. Martini M, Vecchione L, Siena S, Tejpar S, and Bardelli A. Targeted therapies: how personal should we go? Nat Rev Clin Oncol. 2011: 9; 87-97
33. Chang AL and Oro AE. Initial Assessment of Tumor Regrowth After Vismodegib in Advanced Basal Cell Carcinoma. Arch Dermatol. 2012: 148; 1324-1325
34. Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, Coppola C, Chanana AM, Marji J, Bickers DR, and Epstein EH Jr. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012: 366; 2180-2188
35. Grachtchouk V, Grachtchouk M, Lowe L, Johnson T, Wei L, Wang A, de Sauvage F, and Dlugosz AA. The magnitude of hedgehog signaling activity defines skin tumor phenotype. EMBO J. 2003: 22; 2741-2751
36. Harris PJ, Takebe N, and Ivy SP. Molecular Conversations and the Development of the Hair Follicle and Basal Cell Carcinoma. Cancer Prev Res. 2010: 3; 1217-1221
37. Hutchin ME, and Kariapper MS, Grachtchouk M, Wang A, Wei L, Cummings D, Liu J, Michael LE, Glick A, and Dlugosz AA. Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle. Genes Dev. 2005: 19; 214-223.
38. Mitsui H, Suárez-Fariñas M, Belkin DA, Levenkova N, Fuentes-Duculan J, Coats I, Fujita H, and Krueger JG. Combined Use of Laser Capture Microdissection and cDNA Microarray Analysis Identifies Locally Expressed Disease-Related Genes in Focal Regions of Psoriasis Vulgaris Skin Lesions. J Invest Dermatol. 2012: 132; 1615-1626
39. Suárez-Fariñas M, Pellegrino M, Wittkowski KM, and Magnasco MO. Harshlight: a "Corrective Make-Up" Program for Microarray Chips. BMC Bioinformatics. 2005: 6; 294-304.